At roughly four months post-launch, the Dupixent patient and user base has experienced substantial growth, though nearly one-third of US dermatologists have yet to see a sales representative according to recent report from Spherix Global Insights Download Report Overview EXTON,…
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update…
According to RealTime Dynamix™: Bone and Mineral Metabolism, a quarterly report published by Spherix Global Insights, the migration to non-calcium based binders, with accelerated adoption of Keryx’s Auryxia and FMC’s Velphoro, is expected to continue Download Report Overview EXTON, Pa.,…
Despite Kevzara’s aggressive pricing play, early launch metrics of the newest IL-6 inhibitor, indicate conservative uptake, according to Spherix Global Insight’s most recent quarterly update Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — Following an unfavorable recommendation from…
According to recent data released from Spherix Global Insights, early US dermatologist’s views of Tremfya leave ground to be covered Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — At two weeks post launch, only half of the surveyed…
According to a new study published by Spherix Global Insights, close to half of the dialysis patients treated with phosphate binders are above the target phosphorus level Download Report Overview EXTON, Pa., Aug. 3, 2017 /PRNewswire/ — According to the…